Clinical Trial Detail

NCT ID NCT03565445
Title A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

prostate cancer

Advanced Solid Tumor

ovarian cancer

breast cancer

pancreatic cancer

head and neck squamous cell carcinoma

lung non-small cell carcinoma

Therapies

ASP1948 + Nivolumab

ASP1948

Age Groups: adult senior

No variant requirements are available.